ST. JOSEPH, Mich., Sept. 2 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that MD Anderson has become a certified GeneGo Center of Excellence. MD Anderson researchers will have institution-wide access to GeneGo’s MetaCore data analysis suite, training and advanced support. MD Anderson specializes in cancer treatment and research and is well known for its advanced clinical trials programs. MetaCore will be used throughout many research programs both as a central data repository, management and collaboration platform for clinical OMICs data and as an integrative pathway analysis suite.
Mary E. Edgerton, a pathologist performing cancer research at MD Anderson and a long-term client, says “I have been using MetaCore for many years in my research into pathways and networks that control aggressive behavior in cancers. I am currently using it to infer networks from analysis of gene expression array data for pathways in lung, brain, and breast cancer. I also use the curated pathways to formulate mathematical models of molecular networks that predict tumor behavior using multiscale modeling. Not only do I find the product to be very useful, but I also appreciate the responsiveness of the staff at GeneGo to my technical questions and suggestions. “
“MD Anderson is renowned for their pioneering work in oncology. I have known some of the MD’s there for a while and I admire their dedication to their patients and to working hard to find cures,” said Julie Bryant, GeneGo’s VP of Business development. “We are proud to have them as an institution customer and a Center of Excellence. We have a large development program in the area of cancer system biology tools supported by NCI and we are glad to see this work appreciated by some of the best oncology professionals in the world working at MD Anderson.”
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company’s web site at http://www.genego.com.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
